Drug Profile
Hyaluronic acid/triamcinolone - Anika Therapeutics
Alternative Names: Cingal; Sodium hyaluronate/triamcinolone hexacetonide; Triamcinolone/Hyaluronic acid - Anika Therapeutics; TrispanLatest Information Update: 10 Aug 2023
Price :
$50
*
At a glance
- Originator Anika Therapeutics
- Class Adjuvants; Analgesics; Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Glycosaminoglycans; Pregnadienes; Small molecules; Urologics
- Mechanism of Action Glucocorticoid receptor agonists; Hyaluronic acid replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preregistration Osteoarthritis
Most Recent Events
- 08 Aug 2023 Anika attendes a Type-C meeting with the US FDA
- 01 Nov 2022 Hyaluronic acid/triamcinolone - Anika Therapeutics is available for licensing in USA, Asia as of 01 Nov 2022. www.anika.com, 9372281
- 01 Nov 2022 Anika Therapeutics plans to discuss the pathway for US regulatory approval for hyaluronic acid/triamcinolone with the US FDA in 2022